An intermittent dosing strategy of direct oral anticoagulants may allow elite athletes requiring long-term anticoagulation to safely participate in contact and collision sports.
Does a personalized intermittent DOAC dosing strategy allow elite athletes requiring long-term anticoagulation to safely participate in contact and collision sports?
A personalized intermittent DOAC dosing strategy may offer a novel approach allowing elite athletes on long-term anticoagulation to safely participate in contact sports, challenging traditional advice to forgo such activities.
Traditionally, the athlete who requires long-term anticoagulation has been told to forgo participation in contact and collision sports. However, a strategy of short-term interruption of anticoagulant therapy may be designed for some athletes, allowing them return to full athletic activity. A personalized pharmacokinetic/pharmacodynamic study of a direct oral anticoagulant (DOAC) may allow athletic participation when plasma drug concentration is minimal and resumption of treatment after the risk of bleeding sufficiently normalizes. Scientific data and uncertainties regarding this approach, as well as practical challenges in the implementation, will be discussed.
Moll et al. (2018) conducted a review in Athletes requiring long-term anticoagulation. Intermittent dosing strategy of direct oral anticoagulants (DOACs) was evaluated. An intermittent dosing strategy of direct oral anticoagulants may allow elite athletes requiring long-term anticoagulation to safely participate in contact and collision sports.